聚基-1 odomain 抑制剂的选择性是由一个独特的带结合口袋介导的
Raymundo Nuñez1, Karina L Bursch1, Savannah J Makowski1
1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
ACS medicinal chemistry letters
|October 15, 2025
概括
选择性多基-1 (PBRM1) 抑制剂提供了新的癌症治疗潜力. 在癌症模型中,PBRM1中独特的氨酸残留是选择性抑制剂结合和疗效的关键.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 聚蛋白-1 (PBRM1) 对PBAF染色体重塑复合体至关重要,通过其基因调节基因转录.
- 向PBRM1基基因对治疗前列腺癌和清细胞细胞癌有很大的希望.
- 现有的 PBRM1 抑制剂往往缺乏选择性,与相关的 SMARCA2/4 原体结合.
研究的目的:
- 阐明新型PBRM1代蛋白抑制剂选择性的分子基础.
- 为了确定负责PBRM1特异性抑制的关键残留物和结合相互作用.
- 在癌症模型中评估选择性PBRM1抑制剂的治疗潜力.
主要方法:
- 进行X射线晶体学以确定与抑制剂PB16结合的PBRM1-BD2的结构.
- 位点定向突变发生,以调查特定的PBRM1残留在抑制剂结合中的作用.
- 基于细胞的测试,以评估PB16在PBRM1-依赖癌症模型中的活性.
主要成果:
- X射线晶体结构揭示了选择性抑制剂PB16与PBRM1-BD2.2的结合模式.
- 突变酶在PBRM1中发现了一种独特的铁氨酸残留物,这种残留物对于产生选择性抑制剂的独特结合口袋至关重要.
- 与其他选择性抑制剂不同,PB16在PBRM1依赖的癌症模型中显示出细胞活性.
结论:
- 在PBRM1中,一种独特的氨酸残留物对选择性抑制剂结合至关重要.
- 在相关模型中,PBRM1抑制剂PB16表现出有前途的抗癌活性.
- PB16代表了开发向癌症治疗的潜在主要候选人.
相关概念视频
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Ligand Binding Sites
8.6K
8.6K
Dose-Response Relationship: Selectivity and Specificity
9.5K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.5K
Conserved Binding Sites
5.0K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.0K
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Protein-Drug Binding: Mechanism and Kinetics
1.6K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K


